Literature DB >> 24135381

Linear IgA bullous disease presenting as toxic epidermal necrolysis: a case report and review of the literature.

Rohit Kakar1, Holly Paugh, Christine Jaworsky.   

Abstract

A 91-year-old female presented with widespread skin sloughing and bullae clinically mimicking toxic epidermal necrolysis (TEN). The patient was on multiple antibiotics, including vancomycin and piperacillin/tazobactam. Histopathology and direct immunofluorescence were consistent with a diagnosis of linear IgA bullous disease (LABD). In a PubMed review of the literature from 1975 to the present, there have been 15 cases of LABD presenting as TEN clinically and with characteristic linear IgA deposits on direct immunofluorescence studies. Vancomycin and phenytoin were the most commonly implicated medications. Twelve patients saw a resolution or healing of skin lesions after discontinuation of the implicated medication. There were, however, 5 patients who died of complications related to their comorbidities. It is important to include LABD in the differential diagnosis when evaluating patients who clinically present with TEN.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24135381     DOI: 10.1159/000353584

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  10 in total

1.  Drug-induced linear immunoglobulin A bullous dermatosis: A French retrospective pharmacovigilance study of 69 cases.

Authors:  Bethsabée Garel; Saskia Ingen-Housz-Oro; Daniele Afriat; Catherine Prost-Squarcioni; Florence Tétart; Benoit Bensaid; Corina Bara Passot; Marie Beylot-Barry; Vincent Descamps; Sophie Duvert-Lehembre; Sabine Grootenboer-Mignot; Géraldine Jeudy; Angèle Soria; Marie Blanche Valnet-Rabier; Annick Barbaud; Frédéric Caux; Bénédicte Lebrun-Vignes
Journal:  Br J Clin Pharmacol       Date:  2019-01-04       Impact factor: 4.335

2.  Vancomycin-induced linear IgA bullous dermatosis.

Authors:  Claire J Wiggins; Susan Y Chon
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-08-26

Review 3.  Thyroid diseases and skin autoimmunity.

Authors:  Enke Baldini; Teresa Odorisio; Chiara Tuccilli; Severino Persechino; Salvatore Sorrenti; Antonio Catania; Daniele Pironi; Giovanni Carbotta; Laura Giacomelli; Stefano Arcieri; Massimo Vergine; Massimo Monti; Salvatore Ulisse
Journal:  Rev Endocr Metab Disord       Date:  2018-12       Impact factor: 6.514

4.  Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States.

Authors:  Derek Y Hsu; Joaquin Brieva; Nanette B Silverberg; Amy S Paller; Jonathan I Silverberg
Journal:  J Am Acad Dermatol       Date:  2017-03-09       Impact factor: 11.527

5.  Previously misdiagnosed linear IgA dermatosis resolved with dapsone.

Authors:  Vinicius Tieppo Francio; Chris Towery; Saeid Davani; Travis Allen; Tony L Brown
Journal:  BMJ Case Rep       Date:  2018-04-25

Review 6.  Bullous lesions in a patient with systemic lupus erythematosus.

Authors:  Jennifer S Ranario; Jennifer L Smith
Journal:  J Clin Aesthet Dermatol       Date:  2014-09

Review 7.  Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity.

Authors:  Katherine C Konvinse; Elizabeth J Phillips; Katie D White; Jason A Trubiano
Journal:  Curr Opin Infect Dis       Date:  2016-12       Impact factor: 4.915

Review 8.  Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:  Marianne Lerch; Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Thomas Harr
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 10.817

Review 9.  Vancomycin-associated linear IgA disease mimicking toxic epidermal necrolysis.

Authors:  Amanda Regio Pereira; Luis Henrique Barbizan de Moura; Jhonatan Rafael Siqueira Pinheiro; Victor Pavan Pasin; Milvia Maria Simões E Silva Enokihara; Adriana Maria Porro
Journal:  An Bras Dermatol       Date:  2016 Sep-Oct       Impact factor: 1.896

Review 10.  Glycopeptide Hypersensitivity and Adverse Reactions.

Authors:  Vanthida Huang; Nicola A Clayton; Kimberly H Welker
Journal:  Pharmacy (Basel)       Date:  2020-04-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.